SBI Mutual Fund increased its stake in Aurobindo Pharma Limited from 1.87% to 3.57%, purchasing 1,87,05,070 shares.
A major manufacturer of active pharmaceutical ingredients and generic pharmaceuticals, Aurobindo Pharma produces a diverse range of pharmaceutical products serving domestic and international markets. The company operates across multiple therapeutic segments and maintains manufacturing facilities that comply with global quality standards. Its vertically integrated operations, coupled with significant research and development capabilities, distinguish it as a key player in India's pharmaceutical sector.
India's largest AMC by total AUM, managing over Rs 11 lakh crore across equity, debt and hybrid schemes. Backed by State Bank of India, the country's largest bank, which gives it unmatched retail reach across every Indian state. With over 70 schemes and 50 million folios, SBI MF's positioning moves are tracked as a proxy for domestic institutional flows.
